Equities analysts expect that Immune Design Corp (NASDAQ:IMDZ) will announce $800,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Immune Design’s earnings, with the highest sales estimate coming in at $1.03 million and the lowest estimate coming in at $570,000.00. Immune Design reported sales of $490,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 63.3%. The firm is expected to report its next quarterly earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Immune Design will report full-year sales of $3.20 million for the current fiscal year, with estimates ranging from $1.70 million to $6.00 million. For the next fiscal year, analysts expect that the firm will report sales of $6.88 million, with estimates ranging from $2.20 million to $16.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Immune Design.

Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. Immune Design had a negative net margin of 2,409.84% and a negative return on equity of 43.44%. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.75 million.

A number of brokerages recently weighed in on IMDZ. Zacks Investment Research raised shares of Immune Design from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Tuesday, October 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Immune Design in a research note on Friday, October 12th. HC Wainwright set a $8.00 target price on shares of Immune Design and gave the company a “buy” rating in a research note on Wednesday, November 7th. Finally, Leerink Swann downgraded shares of Immune Design from an “outperform” rating to a “market perform” rating in a research note on Friday, October 12th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Immune Design has an average rating of “Buy” and an average price target of $7.25.

A number of institutional investors and hedge funds have recently made changes to their positions in IMDZ. Dimensional Fund Advisors LP grew its position in Immune Design by 132.4% during the second quarter. Dimensional Fund Advisors LP now owns 447,026 shares of the biotechnology company’s stock valued at $2,034,000 after acquiring an additional 254,696 shares during the last quarter. BlackRock Inc. grew its position in Immune Design by 10.6% during the second quarter. BlackRock Inc. now owns 2,121,271 shares of the biotechnology company’s stock valued at $9,651,000 after acquiring an additional 204,171 shares during the last quarter. DRW Securities LLC grew its position in Immune Design by 59.2% during the second quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 21,900 shares during the last quarter. Alps Advisors Inc. bought a new position in Immune Design during the second quarter valued at approximately $318,000. Finally, Portolan Capital Management LLC bought a new position in Immune Design during the second quarter valued at approximately $2,024,000. 49.02% of the stock is currently owned by institutional investors and hedge funds.

Shares of Immune Design stock traded up $0.04 on Friday, reaching $1.35. The stock had a trading volume of 6,647 shares, compared to its average volume of 582,779. Immune Design has a 1 year low of $1.25 and a 1 year high of $5.05. The company has a market cap of $65.02 million, a price-to-earnings ratio of -0.77 and a beta of 2.54.

Immune Design Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

See Also: What is insider trading?

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.